World Cancer Report. Lyon: IARC Press, 2003., , Eds.
2006. website: www.cancer.org; Cancer Facts and Figures
Cancer Facts & Figures 2009. Atlanta: American Cancer Society; 2009..
Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased-array coils. Radiology 1991; 193: 703–09., , , , , , et al.
The prostate: MR imaging and spectroscopy. Present and future. Radiol Clin North Am 2000; 38: 115–38, viii–ix., , , , , .
Normal anatomy of the prostate and changes in benign hypertrophy and carcinoma. Semin US CT MR 1988; 9: 329–34..
Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostatic biopsy: A pilot study. J Urol 1999; 162: 1314–7., , , , , , et al.
In vitro high resolution 1H-spectroscopy of the human prostate: Benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma. Magn Reson Med 1993; 29: 285–91., , , , .
Magnetic resonance with endorectal coil in the local staging of prostatic carcinoma. Comparison with histologic macrosections in 40 cases. Radiol Med (Torino) 1999; 97: 491–8., , , , , , et al.
Prostate cancer: Effect of postbiopsy hemorrhage on interpretation of MR images. Radiology 1995; 195: 385–90., , , , , , et al.
Hormonal ablation of prostatic cancer: Effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging. Am J Roentgenol 1995; 166: 1157–63., , , , , , et al.
Local staging of prostate cancer using magnetic resonance imaging: A meta-analysis. Eur Radiol 2002; 12: 2294–302., , , , , .
Citrate in the diagnosis of prostate cancer. The Prostate 1999; 38: 237–45., , .
The intermediary metabolism of the prostate: A key to understanding the pathogenesis and progression of prostate malignancy. Oncology 2000; 59: 269–82., .
The role of citric acid in the physiology of the prostate: A preliminary report. J Urol 1959; 81: 157–63., .
The role of citric acid in the physiology of the prostate: Lactic/citrate rations in benign and malignant prostatic homogenates as an index of prostatic malignancy. J Urol 1984; 92: 533–6., .
Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells. J Biol Chem 1997; 46: 28875–81., , , .
Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. The Prostate 1998; 35: 285–96., .
Zinc concentration in human prostatic fluid: Normal, chronic prostatitis, adenoma and cancer. Int Urol Nephrol 1996; 28: 687–94., , .
hZIP1 is a major zinc uptake transporter for the accumulation of zinc in prostate cells. J Inorg Biochem 2003; 96: 435–42., , , , , .
Zinc in the human prostate gland: Normal hyperplasia, cancerous. Int Urol Nephrol 1997; 29: 565–74., , .
Zinc causes a shift toward citrate at equilibrium of the m-aconitase reaction of prostate mitochondria. Inorg Biochem 2000; 78: 161–5., , , .
Studies of human tumors by MRS: A review. NMR Biomed 1992; 5: 303–24..
In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng 2005; 7: 287–326., .
Bioenergetic theory of prostate malignancy. Prostate 1994; 25: 162–6., .
Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. Magma 2000; 10: 153–9., , , , , .
Polyamine-dependent gene expression. Cell Mol Life Sci 2003; 60: 1394–406., , .
Polyamines as modifiers of genetic risk factors in human intestinal cancers. Biochem. Soc Trans 2003; 31: 388–92., .
Citrate alterations in primary and metastasis human prostatic Aden carcinomas: 1H magnetic resonance spectroscopy and biochemical study. Magn Reson Med 1993; 29: 149–57., , , , , .
Differentiation of human prostate cancer from benign hypertrophy by in vitro 1H NMR. Magn Reson Med 1992; 25: 140–7., , , , , , et al.
Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy. J Urol 1993; 150: 2019–24., , , , , , et al.
Transrectal probe for 1H MRI and 31P MR spectroscopy of the prostate gland. J Magn Reson 1989; 11: 209–20., , , , , , et al.
Magnetic resonance spectroscopy in prostate disease: Diagnostic possibilities and future developments. Prostate 1992; 4: 43–50., .
1H MR spectroscopy of normal and malignant human prostate in vivo. J Magn Reson 1990; 87; 610–9., , , , .
Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: Detection via localized proton spectroscopy. Urology 1995; 45; 459–66., , , , , , et al.
Proton MR T2 maps correlate with the citrate concentration in the prostate. NMR Biomed 1996; 9: 59–64., , , , , , et al.
In vivo quantification of citrate concentration and water T2 relaxation time of the pathologic prostate gland using 1H MRS and MRI. Magn Reson Imag 1997; 15: 1177–86., , , , , .
Localized high-resolution proton NMR spectroscopy using echoes: Initial applications to human brain in vivo. Magn Reson Med 1989; 9: 79–93., , , , , .
Spatial localization in NMR spectroscopy in vivo. Ann NY Acad Sci 1987; 508: 333–48..
Proceedings of Soc of Magn Reson Med, 12th annual meeting, New York, 1993, p. 213., , , , , , et al. 1H MRS of prostate pathology. In
Practical applications of chemical shift imaging. NMR Biomed 1992; 5: 238–43..
NMR chemical shift in three dimensions. Proc Natl Acad Sci USA 1982; 79: 3523–6., , .
In vivo MR spectroscopic imaging with P-31. Work in progress. Radiology 1984; 153: 745–50., , , .
Acquisition and quantitation in proton spectroscopy. NMR Biomed 1991; 4: 64–9., , den HJ.
Improved water and lipid suppression for 3D PRESS CSI using RF Band selective inversion with gradient dephasing (BASING). Magn Reson Med 1997; 38: 311–21., , , , .
Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn Reson Med 2000; 43: 23–33., , , , , , et al.
Improved solvent suppression and increased spatial excitation bandwidths for three-dimensional PRESS CSI using phase-compensating spectral/spatial spin-echo pulses. J Magn Reson Imaging 1997; 7: 745–57., , , , .
Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging. Magn Reson Med 2000; 43: 17–22., , , , , , et al.
Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7 cm3) spatial resolution. Radiology 1996; 198: 795–805., , , , , .
Human prostate: Multisection proton MR spectroscopic imaging with a single spin-echo sequence – preliminary experience. Radiology 1999; 213: 919–25., , , , .
Sextant localization of prostate cancer; comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000; 164: 400–04., , .
Transition zone prostate cancer: Metabolic characteristics at 1H spectroscopic imaging – initial results. Radiology 2003; 229: 241–7., , , , , , et al.
Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: Value of MR imaging. Radiology 2002; 224: 701–06., , , , , , et al.
Prostate biopsy strategies: Past, present, future. Urol Clin North Am 2002; 29: 205–12..
Intraoperative conformal optimization for transperineal prostate implantation using magnetic resonance spectroscopic imaging. Cancer J 2000; 6: 249–55., , , , , , et al.
Treatment planning for prostate implants using magnetic resonance spectroscopy imaging. Int J Radiation Oncology Biol Phys 2000; 47: 1085–96., , , , , , et al.
Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys 1999; 44: 921–9., , , , .
Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. Int J Radiat Oncol Biol Phys 2001; 51: 244–54., , , , 3rd.
Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002; 52: 429–38., , , , , , et al.
Prostate cancer tumor volume: Measurement with endorectal MR and MR spectroscopic imaging. Radiology 2002; 223: 91–7., , , , , , et al.
Prostate cancer: Endorectal MR imaging and MR spectroscopic imaging – distinction of true-positive results from chance-detected lesions. Radiology 2006; 238: 192–9., , , , , , et al.
Towards integrating functional imaging in the treatment of prostate cancer with radiation: The registration of the MR spectroscopy to ultrasound/CT images and its implementation in treatment planning. Int J Radiat Oncol Biol Phys 2002; 54: 1558–64., , , .
Deformable image registration for the use of magnetic resonance spectroscopy in prostate treatment planning. Int J Radiat Oncol Biol Phys 2004; 58: 1577–83., , , .
Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 2004; 233: 441–8., , , , , 3rd, et al.
Prostate cancer: Correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 2005; 236: 545–53., , , , , , et al.
Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys 2004; 59: 665–73., , , , , , et al.
Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004; 60: 1047–55., , , , , 3rd.
Prostate cancer: Prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999; 213: 481–8., , , , , , et al.
Prostate cancer tumor volume: Measurement by endorectal MR imaging and MR spectroscopic imaging. Radiology 2002; 223: 91–7., , , , , , et al.
Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia 2000; 2: 166–89., , .
Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate. Magn Reson Med 2004; 52: 80–8., , , , , .
Optimal timing for in vivo 1H-MR spectroscopic imaging of the human prostate at 3 T. Magn Reson Med 2005; 53: 1268–74., , , , , Barentsz, .
Magnetic resonance imaging and spectroscopic imaging of prostate cancer. Cancer Invest 2001; 19: 510–23., , , .
Prostate depiction at endorectal MR spectroscopic imaging: Investigation of a standardized evaluation system. Radiology 2004; 233: 701–08., , , , , , et al.
Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathological analysis after radical prostatectomy. Radiology 2005; 234: 804–14., , , , , , et al.
Removal of the outer lines of the citrate multiplet in proton magnetic resonance spectra of the prostatic gland by accurate timing of a point-resolved spectroscopy pulse sequence. MAGMA 1994; 5: 65–9., , .
Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T. Magn Reson Med 2005; 53: 1033–9., , , , , , et al.
2D JPRESS of human prostates using an endorectal receiver coil. Magn Reson Med 2002; 47: 1059–64., , , .
Fast multi-voxel two-dimensional spectroscopic imaging at 3 T. Magn Reson Imaging 2007; 25: 1144–61., , .
In vivo prostate magnetic resonance spectroscopic imaging using two-dimensional J-resolved PRESS at 3 T. Magn Reson Med 2005; 49: 1177–82., , , , .
MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: Preliminary results. Radiology 2004; 230: 652–9., , , .
MRI of prostate cancer at 1.5 and 3.0 T: Comparison of image quality in tumor detection and staging. Am J Roentgenol 2005; 185: 1214–20., , , , , , et al.
Determinations of prostate volume at 3-Tesla using an external phased array coil: Comparison to pathologic specimens. Acad Radiol 2003; 10: 846–53., , , , .
MR imaging of the prostate at 3 Tesla: Comparison of an external phased-array coil to imaging with an endorectal coil at 1.5 Tesla. Acad Radiol 2004; 11: 857–62., , , , , .
3-Tesla magnetic resonance imaging of the prostate with combined pelvic phased-array and endorectal coils initial experience. Acad Radiol 2004; 11: 863–7., , , , .
Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: Feasibility. Radiology 2007; 245: 507–16., , , , , , et al.
Initial experience of 3 Tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Invest Radiol 2004; 39: 671–80., , , , , , et al.
In vivo prostate magnetic resonance imaging and magnetic resonance spectroscopy at 3 Tesla using a transceiver pelvic phased array coil. Invest Radiol 2003; 38: 443–51., , , , , , et al.
Anatomical and metabolic assessment of prostate using a 3-Tesla MR scanner with a custom-made external transceiver coil: Healthy volunteer study. J Magn Reson Imaging 2007; 25: 517–26., , , , , , et al.
Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. J Urol 2000; 164: 759–63., , , , , , et al.
Combined MRI and MR spectroscopy of the prostate before radical prostatectomy. Am J Roentgenol 2006; 187: 724–30., , , , , , et al.
MRI and MRSI of prostate cancer prior to radical prostatectomy: A prospective multi-institutional clinicopathological study. Chicago: RSNA, 2006, , , , , . ACRIN 6659:
Diffusion imaging of the prostate at 3.0 Tesla. Invest Radiol 2006; 41: 185–8., , .
Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0 T. J Magn Reson Imaging 2006; 23: 130–4., , , .
Diffusion-weighted imaging of prostate cancer. J Comput Assist Tomogr 2005; 29: 149–53., , , , , , et al.
Dynamic contrast enhanced MRI of prostate cancer: Correlation with morphology and tumor stage, histological grade and PSA. Clin Radiol 2000; 55: 99–109., , , , , , et al.
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. The Prostate 2004; 62: 140–7., , , , .
Accurate estimation of pharmacokinetic contrast enhanced dynamic MRI parameters of the prostate. J Magn Reson Imaging 2001; 13: 607–14., , .
Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using contrast-enhanced MR imaging. Radiology 2003; 229: 248–54., , , , , , et al.
Prostate cancer: Evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging – initial experience. Radiology 2004; 233: 709–15., , , .
Combined quantitative dynamic contrast enhanced MR imaging and 1H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 2004; 20: 279–87., , , , , , et al.
Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: Early experience. Radiology 2005; 236: 903–10., , , Jr, .
Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: A systematic review and meta-analysis. Eur Urol 2009; 55: 575–91., , , , , , et al.